ORION CORPORATION STOCK EXCHANGE RELEASE
Composition of the
The Board of Directors of
Annika Ekman Erkki Etola Petteri Karttunen Matti Kavetvuo Timo Maasilta Heikki Westerlund Jukka Ylppö
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.
The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at https://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/ , a page in the Corporate Governance section of the Orion Group internet website.
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 3692
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to
© OMX, source